Biogen v. Glaxosmithkline: Prosecution History Disclaimer and Claim Construction Patently-O Rituximab binds to this epitope. After Biogen filed its application, other scientists discovered that the CD20 antigen had a second small loop (originally thought to be hidden inside the cell) to which other, different anti-CD20 antibodies could bind ... Federal Circuit Finds Prosecution History Disclaimer In Enablement Arguments |
